

Annual Report 2015

A Letter from Our Chair of the Board and CEO...

... A Year of Breakthroughs

Dear Friends,

It became apparent this year that all of us together are greater than bladder cancer. In fact, 2015 is best summarized as a breakthrough year. We doubled the number of patients reached through our programs and educational support services by empowering them with vital tools and information and embarked on the most promising research initiative in the Bladder Cancer Advocacy Network's (BCAN) ten-year history.

Advocacy efforts are critical to our mission and BCAN volunteer advocates are uniquely positioned and trained to respond to a broad array of issues involving bladder cancer. This year we heightened our efforts to shape and influence federal legislation by visiting members of Congress during our Hill day. In 2015, we were successful in securing a Senate resolution declaring May as "National Bladder Cancer Awareness Month" and thanks to the tremendous efforts of our volunteer advocates, voices of the bladder cancer community were heard all over the country.

BCAN observed its ten-year anniversary with celebration and reflection. This milestone commemorated with a gala recognizing the many volunteers and donors that helped to shape the organization into what it is today and by looking forward to the promises of tomorrow.

With the ultimate goal to provide every patient with the opportunity to be an exceptional responder to personalized therapy, BCAN launched the Bladder Cancer Genomics Consortium (BCGC). A collaboration of eight leading academic medical institutions, BCGC's first project is a large-scale genomics bladder cancer study.


Our 2015 successes are a testament to the visionary leadership of Co-Founder Diane Zipursky Quale, and we are honored to continue building on her legacy.

Finally, as we move into the world with more emphasis on bladder cancer and our mission to increase public awareness about bladder cancer, advance bladder cancer research, and provide educational and support services for the bladder cancer community, we know that our progress is a result of the generosity of BCAN's supporters and volunteers. We remain grateful for your passion and commitment to a world free from bladder cancer.

With great appreciation for your support,



Andrea Maddox-Smith
Chief Executive Officer



Gerald McNamara
Chair of the Board



The Bladder Cancer Think Tank collaborated in North Carolina.



May was declared "National Bladder Cancer Awareness Month."



"BCAN TEN!" celebrated BCAN's ten-year anniversary.



BCGC was launched, focusing on personalized medicine.

National Bladder Cancer Awareness Month

114TH CONGRESS
1ST SESSION

S. RES. 187

Expressing support for the designation of the month of May 2015, as
“National Bladder Cancer Awareness Month”.

IN THE SENATE OF THE UNITED STATES

MAY 21, 2015

Mr. MENENDEZ (for himself, Mr. ISAKSON, and Mr. SCHUMER) submitted the
following resolution; which was considered and agreed to

RESOLUTION

Expressing support for the designation of the month of May
2015, as “National Bladder Cancer Awareness Month”.

Whereas 500,000 families in the United States live with bladder cancer;

Whereas more than 74,000 people are expected to be diagnosed with bladder cancer and 16,000 will die due to the disease in 2015 alone;

Whereas bladder cancer affects people of all ages and backgrounds and is among the top 10 cancers with the highest incidence rates in the United States;

Whereas bladder cancer is known as one of the most expensive cancers to treat on a per patient basis with a recurrence rate of approximately 50 to 80 percent, requiring lifelong surveillance;

Whereas bladder cancer symptoms, such as blood in the urine, are easily recognized, however, many are unaware of the threat of bladder cancer, often prolonging the time to diagnosis;

Whereas if diagnosed early, bladder cancer is treatable;

Whereas military veterans are twice as likely as nonveterans to be diagnosed with bladder cancer;

Whereas women are often diagnosed at a later stage in the development of bladder cancer, and when diagnosed at the same stage as men, women have a worse prognosis;

Whereas if diagnosis and treatment are delayed, the life expectancy of an individual with bladder cancer decreases;

Whereas the quality of life of a person with bladder cancer will depend on future treatment and diagnosis developments, which will rely on research advancements;

Whereas there have been no new treatments approved by the Food and Drug Administration for bladder cancer in over 10 years;

Whereas research advancements for bladder cancer are limited by lack of awareness about the disease within the medical community and general public;

Whereas increased awareness will promote early diagnosis and increase the chances of survival;

Whereas increased awareness will bolster public support of the disease and thus increase funding for innovative research and the development of new treatment options and diagnostic tools;

Whereas traditionally on the first Saturday in May each year, survivors, caregivers, and loved ones walk together throughout the United States to raise awareness of bladder cancer;

Whereas the Bladder Cancer Advocacy Network and its community of patients, caregivers, and specialists seek—

(1) to foster a community of hope and support;

(2) to fund and conduct research for innovative treatments and diagnostic tools; and

(3) to increase public awareness and understanding of bladder cancer; and

Whereas May would be an appropriate month to designate as “National Bladder Cancer Awareness Month”: Now, therefore, be it

Resolved, That the Senate—

(1) supports the designation of May 2015, as

“National Bladder Cancer Awareness Month”;


(2) supports the goals and ideals of National Bladder Cancer Awareness Month; and

(3) calls on the people of the United States, interested groups, and affected persons—

(A) to promote awareness of bladder cancer and to foster understanding of the impact of the disease on patients and their families and caregivers;

(B) to take an active role in the fight to end bladder cancer; and

(C) to observe National Bladder Cancer Awareness Month with appropriate ceremonies and activities.



"BCAN TEN!" marked the celebration and reflection of our first decade, while inspiring future BCAN initiatives.





Walk for Bladder Cancer®

Leading the way to a cure

During the month of May, the bladder cancer community came together across the nation to raise awareness and funds.





**BLADDER
CANCER
GENOMICS
CONSORTIUM**

Creating the opportunity for every bladder cancer patient to be an exceptional responder

Introducing an innovative collaboration between the Bladder Cancer Advocacy Network (BCAN) and major medical centers to develop an enriched understanding of the genomic profile of bladder cancer and facilitate the development of novel therapeutics. This \$1.6 million investment through private philanthropy will increase collaborative research to improve outcomes for bladder cancer patients.

PRECISION MEDICINE IN BLADDER CANCER



The Cancer Genome Atlas (TCGA) results suggest potential therapeutic targets in 70% of bladder cancer tumors.



More than 32 genes have been identified as playing a critical role in bladder cancer biology.



Additional sequencing and sharing of data is needed to identify those molecular alterations that are most likely to be actionable and impacted by targeted treatments.

Pilot Project: UC-GENOME

Urothelial **C**ancer-**GENO**mic analysis to **i**mprove patient outcomes and **r**Esearch



Enroll 200 metastatic bladder cancer patients



Tumor tissue sent for Next Generation Sequencing (NGS) at no cost to patient or institution



Patients and their physicians receive a comprehensive report on potential treatments and clinical trials of novel therapeutics based on the genomic profile of their tumor



De-identified biospecimens and clinical information housed in a central biorepository and database for collaborative research opportunities

Study management provided by:



Next Gen Sequencing provided by:







At the annual Bladder Cancer Think Tank, participants focused on identifying obstacles and creating solutions in bladder cancer research, fostering discussions to help define priorities for advancing bladder cancer research.




BCAN Memorable Moments



BCAN Volunteers, Chapters, and Support Groups made every effort to ensure the bladder cancer community was represented and had a strong voice from coast to coast through advocacy, fundraisers, health and lunch fairs.



2015 Bladder Cancer Research Innovation Award Winner



JAMES FAMILY FOUNDATION AND PARTNER FUND MANAGEMENT BLADDER CANCER RESEARCH INNOVATION AWARD

Cory Abate-Shen, Ph.D.

Professor of Urological Oncology at Columbia University Medical Center and Associate Director of Translational Research at the Herbert Irving Comprehensive Cancer Center
“Epigenetic regulation of bladder cancer progression.”

2015 Young Investigators

THE STEPHEN HALE GUSHÉE YOUNG INVESTIGATOR AWARD

Rahul Parikh, M.D., Ph.D.

University of Pittsburgh

“The Role of ATM Loss and the ATR-CHK1 Pathway in Bladder Cancer”



THE MIRIAM GLEBERMAN YOUNG INVESTIGATOR AWARD

Philip Palmbo, M.D., Ph.D.

University of Michigan

“The Role of TP63 and ATDC in Invasive Bladder Cancers”

2015 John Quale Travel Fellows

Abdul R. Banday, Ph.D., M.S.

National Cancer Institute

Max Kates, M.D.

Johns Hopkins Medical Institutions

Huyen T. Nguyen, Ph.D.

The Ohio State University

Randy Sweis, M.D.


University of Chicago



2015: The Year at a Glance

Income Growth


2015 Total = \$3,575,438



■ = BCGC

Expense Composition

2015 Total = \$2,061,030



Additional Highlights in 2015

BCAN launched the Survivor 2 Survivor program, connecting newly diagnosed patients with a volunteer survivor who provides their firsthand account of life with a bladder cancer diagnosis.

“The New Normal: Living with a Urinary Diversion” videos introduced eight bladder cancer survivors giving voice to their choice to let others know about living well with a urinary diversion.

The PCORI supported Patient Survey Network started with over 800 participants providing input on research questions that are important to bladder cancer patients.



Thank You to our Generous Donors

*The following list includes individual donors who contributed \$500 and higher between January 1, 2015 and December 31, 2015.
We appreciate the generosity of all of our supporters.*

\$100,000 - \$249,000

Gerald McNamara and Renée Petrofes

\$25,000 - \$49,999

David Hoffman and Joan Sarnat

Joseph H. Gleberman

\$10,000 - \$24,999

Suzanne Andracki

Jordan and Kim Dickstein

The Estate of Marilyn Flynn Gushée

David and Carol Pulver

Andrew and Sally Quale

William U. Shipley, M.D. , FACR and Jenise Shipley

\$5,000 - \$9,999

Anonymous

Antoinette Bush

Stephanie Greenberg

Mary C. Gushée

John Holmes

Andrea Kasarsky

Robert and Abby Levin

Fred and Marlene Malek

Jessica Newsome and Jane Pancheco

Diane Zipursky Quale

Mace Rosenstein and Louise de la Fuente

Bob and Pat Schieffer

Michael Sobel

Jeff Webb

K. David Weidner, Ph.D. and William Gannon, M.D.

Morley and Charlotte Zipursky

\$1,000 - \$4,999

Wick Allison

Lamberto Andreotti

Shawn Anglum

Anonymous

Henri Bagdahdi

Rick Bangs

Martin Baucom

Carolyn Bechtel

Ambaw Bellette

James Bondi

Brooksley Born

Earle Burgess

Rachel Camarena

Tressa Caldwell

Tom Campbell

Cheryl Chiuchiarelli

Cheryl Coviello

Susan Donahue

Thomas and Cindy Duffy

Beth Fascitelli

Barbara J. Field

Joyce C. Fisher

Joseph P. Flanagan

Samantha Francesca

Ken Gertz

Bart Gohmann

Marlys Gramley

Thomas Green

Erika R. Greenfield

David Grossman

Lauryn Guttenplan

Cynthia Hardie

Mark Himelstein

Nancy E. Hogan

Mary Hultar

Steve Johnson

Elaine Johnston

Julianna Kasper

Bobbie Kern

Rony and Ana Kessler

Sue Kolaga

Cheryl Taylore Lee, M.D.

Seth Lerner, M.D. and Karen Lerner

Peter Lipman

Robert Lipman

Marlene A. Malek

Stephen McCourt

Edward G. McDougall

Andrew Mohr

Natasha Moore

William Moroney

Jim and Ellen Myerberg

Mike Nash

Kelly Nash

E. R. Newman

Michael Panzara

Lawrence Patrick

Kathryn Patton

Wally Podbielski

Brian D. Pokropski

Carol Pullman

Mark and Teresa Quale

Mary Eleanor Roberts

Mike Salvino

Martin Sarver

Ronald Saunders

David Schlee

Mark P. Schoenberg

James Screeden

Jo Ann Sears

Jared Sher

Neal Shore

Robert N. Steckler



Thank You to our Generous Donors

*The following list includes individual donors who contributed \$500 and higher between January 1, 2015 and December 31, 2015.
We appreciate the generosity of all of our supporters.*

\$1,000 - \$4,999 (continued)

Gary Steinberg, M.D.
William Steingrandt
Malcolm Tuesley
Jacqueline Vanier
Kevin Watson
Carol Weida
Erica Wolfe
Karrie Wright
Alisa Zipursky
Richard E. Zoyhofski

Connie Chesser
Lucinda Cloutier
David Cohen
Gabrielle Conklin
Elena Cox
Daria De Piro
George S. Dembroski
Marianne DePippo
Joseph DeTommaso
Thomas Dillon
Robert M. Dolman
Ronald L. Douglas

Harry Herr
Ira Hersh
Jean Hoffman-Censtis, M.D.
John Hren
Beata Jachulski Baker
David Jedd
Curtis A. Johnson
Meredith Jones
Dean Junkans
Christina Jurik
Adam Jurik
Larry Karsh
John Keogh

\$500 - \$999

Jodi Aase
Joseph Alexander
Bonita Allinder
Cynthia Anderson
Tony Angiuli
Steve Arnold
Christopher Ausobsky
Kelly Austin
Sam Awotwi
Ann Barth
James Bayes
Kim Beaudoin
Robert Beizer
Cynthia Berg
Kevin Brady
Nathaniel Brown
Gregory Brown
Henry Bulifant
Michael Burton
Nina Butler
Sara Call
Denis Campbell
Viresh Chana

Barbara Edelin
Harriette Evans
Gary Falcone
David Farber
Kurt J. Faxon
Paul Fayad
Nancy Fitzgibbons
Fred Fletcher
Marvin and Cookie Friedman
Claudia Galbo
Tullika Garg
Tom Gephardt
Bridget Gibson
John Giegerich
Jamie and Andrea Gillespie
John Giuiano
Michael M. Goldstein
Helen B. Gray
Dennis Greenwald
Susan G. Guttman
Sharon Hagen
John H. Haire
Laurie Harvey
Roslyn Hees

Renata Khoshroo
Mary King
Laurence Klurfeld
Diana Kolaitis
Lewis Kramer
Neil Kurtz
Ben Lavon
Jane Lee
Don Levsen
Donald Litke
Ron Madison
Linda Magram
Carol Martin
Erik Martin
Edmund McAlister
Iris H. Medvid
Lynn Miller
Karen Millward
Ed Murphy
Charlotte D. Nau
Henry Neuberger
Wayne Norbitz
Jay and Lisa O'Donnell



Thank You to our Generous Donors

*The following list includes individual donors who contributed \$500 and higher between January 1, 2015 and December 31, 2015.
We appreciate the generosity of all of our supporters.*

\$500 - \$999 (continued)

Jeffrey Parker	Caroline B. Sory
Rakesh Patel	James Stadtmueller
Elizabeth Patterson	Judith Stein
Jennifer Pietenpol	Lila Stenzel
Betsy Plimack	Teresa Vincent
Barbara Powell	Ann Tiller
Melissa Price	David Tilles
Thomas W. Queen	Maureen Denise Tropea
Laura T. Renshaw	Teri Trotter
Howard F. Robins	Edward Van Horne
Cynthia Rossetti	Becki Veal
Stefanie Roth	Bruno Viscariello
Carol Ruffo	Julie F. Walker
Susan Sajadi	Mira Weiss
Jennifer L. Sale	Jay Welker
Mark Sank	Dennis Welzenbach
Kenneth I. Schaner	Mary Jean White
Paul Schreiber	Guy Whittington
David Schulman	Howard Wilkins
Jenna Scrivano	Madeleine Williams
Brenda K. Segall	Pam Wilson
Frank Sharp	Joyce Wilson
John Sherbin	Jill Wollins
Larry Sidman	Susan M. Wood
Timothy Smith	Cheryl Wright
Mark S. Soloway	Mark Young



Thank You to our Generous Corporations, Foundations, and Organizations

The following list includes corporations, foundations, and organizations who contributed \$500 and higher between January 1, 2015 and December 31, 2015.

\$250,000 +

The James Family Foundation

\$100,000 - \$249,000

Genentech, Inc.

a member of Roche Group

The JPB Foundation

\$50,000 - \$99,000

Merck

Photocure

\$25,000 - \$49,999

Bristol-Myers Squibb Foundation

Eli Lilly and Company

Endo Pharmaceuticals

Karl Storz Endoscopy-America, Inc.

Olympus

OncoGenex Technologies, Inc.

Onyx Pharmaceuticals, Inc.

\$10,000 - \$24,999

Abbott Molecular

The Ashley Family Foundation, Inc.

The Dana Foundation

Direct TV Inc.

Heat Biologics, Inc

IOS Press

National Association of Broadcasters

Pacific Edge Diagnostics

PhrMA

Taris Biomedical, LLC

Telesta Therapeutics

TheraCoat Ltd. (now UroGen Pharma)

Viventia Bio, Inc.

\$5,000 - \$9,999

University of Colorado Cancer

Mildred Hoit, Inc.

Local Independent Charities Of America (LICA)

The Mount Sinai School of Medicine

\$1,000 - \$4,999

21st Century Fox America, Inc.

Albany Medical Center

Blackburn & Company Incorporated

Central Nassau County/Rotary Foundation Inc.

Enterprise Holdings, Inc.

Fine Mark National Bank Trust

Illinois Shotokan Booster Club

Inspire/ClinicaHealth Inc.

J. McLaughlin

The J.M. Rubin Foundation

JPA Health Communications

LMCG Investments, LLC

Marcy and Leona Chanin Foundation, Inc.

Maryland Charity Campaign

MD Anderson Cancer Center

The Benevity Community Impact Fund

Melva Bucksbaum Family Foundation

BCAN NC Triangle Chapter

Pace Family Trust

Redstone Federal Credit Union

Ritchers of Palm Beach

Rush Enterprises, Inc.

Small Army for a Cause, Inc.

The Lagomarsino Foundation

The Margolis Foundation, Inc.

The Thompson Group at Morgan Stanley

Tuality - OHSU Cancer Center

The Urological Institute of Northeastern
New York

University of Michigan Comprehensive
Cancer Center

Silicon Valley Community Foundation

\$500 - \$999

AXA Art Americas Corporation

Beallsville Sportsmans Club

Bravelets, LLC

Cohen Mohr LLP

Loffler Companies, Inc.

Dorfman Mizrach & Thaler, LLP

Evelyn and Arthur, Inc.

Greater Lehigh Valley WOCN

Houghton Mifflin

Metro Bowhunters Resource Base Inc.

Michigan Institute of Urology, P.C.

Monetta Group

North Alabama Urology, P.C.

Perkins Coie Foundation

Pioneer Linens

Scanport, Inc.

The Edward and Lucille Kimmel
Foundation, Inc.

The Urology Group

Wiley Rein LLP



Board of Directors

Gerald C. McNamara, *Chair of the Board*
Diane Zipursky Quale, *Co-Founder*
Robert Levin, *Treasurer*
Jared Sher, *Secretary*
Beverly James
Cheryl T. Lee, M.D.
Seth Lerner, M.D., FACS
David Pulver
Mace Rosenstein
William U. Shipley, M.D., FACS

Staff *Updated as of 2016

Andrea Maddox-Smith, *Chief Executive Officer*
Stephanie Chisolm, PhD, *Director of Education and Research*
Anita Parker, *Director of Development*
Alejandra Spangler, *Education and Research Manager*
Trenny Stephens, *Office Manager*
Rebecca Yannopoulos, *Walk Manager*

BCRN Management Committee

Hikmat Al-Ahmadie, M.D.
Memorial Sloan-Kettering Cancer Center
Jessie Au, PharmD., PhD
Optimum Therapeutics
Dean F. Bajorin, M.D.
Memorial Sloan-Kettering Cancer Center
Robert Dreicer M.D., MS
University of Virginia
David M. Latini, PhD
Baylor College of Medicine
Seth Lerner, M.D., FACS
Baylor College of Medicine
Yair Lotan, M.D.
UT Southwestern Medical Center
David J. McConkey, M.D., PhD.
MD Anderson Cancer Center

Matthew I. Milowsky, M.D.
UNC Lineberger Comprehensive Cancer Center
William U. Shipley, M.D., FACS
Harvard Medical School and Massachusetts General Hospital
Eila Skinner, M.D.
Stanford University
John A. Taylor, III, M.D., M.S.
University of Connecticut
Diane Zipursky Quale
Gary D. Steinberg, M.D., FACS (Ex-officio)
University of Chicago

Scientific Advisory Board

Gary D. Steinberg, M.D., FACS, *Chairperson*
University of Chicago
Hikmat Al-Ahmadie, M.D.
Memorial Sloan-Kettering Cancer Center
Andrea Apolo, M.D.
National Cancer Institute
Jessie Au, PharmD., Ph.D.
Optimum Therapeutics
Dean F. Bajorin, M.D.
Memorial Sloan-Kettering Cancer Center
Bernard Bochner, M.D.
Memorial Sloan-Kettering Cancer Center
Sam Chang, M.D.
Vanderbilt University School of Medicine
Michael Cookson M.D.
University of Oklahoma College of Medicine
Guido Dalbagni, M.D., FACS
Memorial Sloan-Kettering Cancer Center
Sia Daneshmand, M.D.
USC/Norris Comprehensive Cancer Center
Colin P.N. Dinney, M.D.
MD Anderson Cancer Center
Robert Dreicer M.D., MS
University of Virginia
Michael Droller, M.D.
Mount Sinai Medical Center
Mario L. Eisenberger, M.D.
Johns Hopkins Medical Institutions

Matthew Galsky, M.D.
Mount Sinai School of Medicine
Scott M. Gilbert, M.D., MS
Moffitt Cancer Center
Mark L. Gonzalgo, M.D., Ph.D.
University of Miami
H. Barton Grossman, M.D., FACS
MD Anderson Cancer Center
Noah M. Hahn, M.D.
Johns Hopkins Medical Institutions
Donna Hansel, M.D., Ph.D.
University of California, San Diego
J. Stephen Jones, M.D., FACS
*Glickman Urological and Kidney Institute
Cleveland Clinic*
Ashish M. Kamat, M.D.
MD Anderson Cancer Center
Larry Karsh, M.D., FACS, CPI
The Urology Center of Colorado
Wassim Kassouf, M.D.
McGill University
Badrinath Konety, M.D., FACS, MBA
University of Minnesota
Donald Lamm, M.D., FACS
BCG Oncology
David M. Latini, Ph.D.
Baylor College of Medicine
Cheryl Lee, M.D., FACS
University of Michigan
Seth Lerner, M.D., FACS
Baylor College of Medicine
Yair Lotan, M.D.
UT Southwestern Medical Center
Kevin Loughlin, M.D., MBA, FACS
Brigham & Women's Hospital
S. Bruce Malkowicz, M.D.
University of Pennsylvania
David J. McConkey, M.D., Ph.D.
MD Anderson Cancer Center
James McKiernan, M.D.
Columbia University
Edward M. Messing, M.D., FACS
University of Rochester Medical Center



BCAN Leadership

Scientific Advisory Board (continued)

Matthew I. Milowsky, M.D.
UNC Lineberger Comprehensive Cancer Center

Matthew Nielsen, M.D.
University of North Carolina at Chapel Hill

Michael O'Donnell, M.D., FACS
Holden Cancer Center, University of Iowa Hospital

Michael Porter, M.D., MS
University of Washington

Raj S. Pruthi, M.D., FACS
University of North Carolina at Chapel Hill

Jonathan E. Rosenberg, M.D.
Memorial Sloan-Kettering Cancer Center

Arthur I. Sagalowsky, M.D.
UT Southwestern Medical Center

Mark Schoenberg, M.D., FACS
Albert Einstein College of Medicine

Shahrokh F. Shariat, M.D.
Medical University of Vienna

William U. Shipley, M.D., FACS
Harvard Medical School and Massachusetts General Hospital

Neal D. Shore, M.D., FACS
*Carolina Urologic Research Center
Grand Strand Urology*

Eila Skinner, M.D.
Stanford University

Norm D. Smith, M.D.
The University of Chicago

Mark Soloway, M.D., FACS
Memorial Healthcare System

Srikala Sridhar, M.D.
Princess Margaret Hospital

Walter Stadler, M.D.
University of Chicago

John A. Taylor, III, M.D., MS
University of Connecticut Health Center

Dan Theodorescu, M.D., Ph.D.
University of Colorado Cancer Center

Steve Wong, M.D.
University of California Los Angeles

Leadership Council

Carol Auerbach

Rosie Bartolotta

Nona Bear

Ambaw Bellele

Jordan Dickstein

Gary Forman

Stacy Robinson Fuller

Mary Gushee

Cynthia Hardie

Calvin Hicks

Christine Keogh Stone

Ella Kot

Simon Lemmy

Ron Stein

K. David Wiedner, Ph.D.

BCAN Chapters

Albany
Denise DiMascio, *President*

Dallas-Forth Worth
Anthony Brewer, *President*

Greater Omaha
Jeff Henrichsen, *President*

Lehigh Valley/Central PA
Marge Coffin, *President*

NC Triangle
David Langham, *President*

New Jersey
Mary Ann Aregood, *Co-President*
Dana Caparoso, *Co-President*

STAY CONNECTED

For the latest BCAN news and bladder cancer information, join us on social media.



@B_C_A_N



bcandotorg



Facebook.com/BladderCancer



@B_C_A_N



Inspire.com/groups/bladder-cancer-advocacy-network